Abemaciclib

• DOSABEMA-Pharmacokinetic model of abemaciclib: correlation with severe diarrhea as the primary toxicity endpoint in patients with hormone re… Pending
  2025-521696-31-00 Phase IV 1 country Centre Hospitalier Universitaire De Poitiers
• A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending
  2025-522791-92-00 Phase III 6 countries Eli Lilly & Co.
• Impact of EXercise on quality of life of early breast cancer patients on treatment with adjuvant Aromatase Inhibitors with or without CDK4/6… Pending
  2025-522848-40-00 Phase IV 1 country Fundacion Grupo Espanol De Investigacion En Cancer De Mama
• A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear… Recruiting
  2023-505661-89-00 Phase II 4 countries Medica Scientia Innovation Research S.L.
• A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting
  2024-512360-55-00 Phase II 9 countries Medica Scientia Innovation Research S.L.
• A Study of Abemaciclib (LY2835219) with Abiraterone in Men with Prostate Cancer that has Spread to Other Parts of the Body and is Expected t… Recruiting
  2022-500461-28-06 Phase III 12 countries Eli Lilly & Co.; Eli Lilly Cork Limited
• To compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participan… Recruiting
  2025-521128-31-00 Phase I/II 4 countries Genentech Inc.
• zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra… Recruiting
  2023-509598-22-01 Phase IV 1 country Champalimaud Clinical Centre; Rita Fior
• A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto… Recruiting
  2023-504180-16-00 Phase III 10 countries AstraZeneca AB
• FINPROVE - The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Recruiting
  2024-517478-68-01 Phase II 1 country HUS-Yhtymae
• A first-in-human dose escalation and expansion study to evaluate the safety, and tolerability of AZD8421 alone or in combination in particip… Recruiting
  2023-507305-33-00 Phase I (FiH) 1 country Astrazeneca AB
• A multicenter uncontrolled, open label, prospective non-comparative single arm phase II study with bicalutamide (an antiandrogen) in combina… Recruiting
  2022-502272-23-00 Phase II 1 country UZ Leuven
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 Phase III 16 countries AstraZeneca AB
• Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib… Recruiting
  2023-503708-10-00 Phase III 8 countries Sermonix Pharmaceuticals Inc.
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting
  2022-502980-39-00 Phase III 13 countries F. Hoffmann-La Roche AG
• IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs – a pragmatic randomized-contr… Recruiting
  2023-506620-87-00 Phase III/IV 6 countries Region Oerebro Laen
• Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A ra… Recruiting
  2023-504141-31-00 Phase II 1 country Institut fuer Klinische Krebsforschung IKF GmbH
• ALEPRO: abemaciclib and letrozole in estrogen receptor positive rare ovarian cancer Recruiting
  2023-503533-21-00 Phase II 3 countries UZ Leuven
• This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a Phase 2 evaluation of elacestran… Recruiting
  2024-512878-98-00 Phase I/II 6 countries Stemline Therapeutics Inc.
• A Study to Evaluate Efficacy and Safety of Multiple Treatment Combinations in Patients with Metastatic Breast Cancer (MORPHEUS-panBC) Recruiting
  2023-503629-20-00 Phase I/II 3 countries F. Hoffmann-La Roche AG
• DRUP trial Recruiting
  2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended
  2024-512925-95-00 Phase III 16 countries Pfizer Inc.
• NEOadjuvant Abemaciclib and GIredestrant triaL in patients with ER-positive, HER2-negative Early breast cancer Ended
  2023-510153-42-00 Phase II 1 country Fondazione Oncotech Impresa Sociale
• A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Ra… Ended
  2022-502269-13-00 Phase II 7 countries Eli Lilly & Co.

Showing 1–24 of 43 trials